Skip to main content

Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)

Objective

We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery
without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.

Coordinator

AMT MEDICAL RESEARCH BV
Net EU contribution
€ 2 497 469,00
Address
Yalelaan 52
3584 CM Utrecht
Netherlands

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 116 593,50